Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with follicular lymphoma (grade 1–3a) that has come back or stopped responding to treatment, confirmed by a biopsy taken within 3 months of joining the trial
• People aged 18 years or older
• People whose lymphoma has advanced to a stage where their treating doctor believes treatment is needed
• People whose doctor considers them suitable for standard available treatments
• People who have previously received at least one course of combined chemotherapy and immunotherapy (prior radiation therapy or rituximab alone does not count as this requirement, though prior rituximab alone is allowed as long as combined immunochemotherapy was also received at some point)
• People whose lymphoma can be measured on a PET-CT scan (at least one affected lymph node larger than 1.5cm, or a lesion outside the lymph nodes larger than 1cm)
• People who are reasonably well and able to carry out daily activities, as assessed by a standard medical scale (ECOG score of 0, 1, or 2) (confirm with trial site)
• People whose heart, liver, kidneys, and blood counts are functioning at an adequate level, as confirmed by blood tests and heart scans (confirm with trial site for specific thresholds)
• People who are able to give written consent to participate
• Women who could become pregnant (or their partners) who are willing to use an effective form of contraception during the trial

Who may not be able to join:

• People whose follicular lymphoma has transformed into a more aggressive (high-grade) lymphoma within the past year, including grade 3b follicular lymphoma (those whose transformation occurred more than one year ago may still be considered eligible)
• People whose lymphoma does not show up clearly on a standard PET-CT scan using the FDG tracer
• People who have previously had an allogeneic stem cell transplant (a transplant using cells from a donor) or a solid organ transplant
• People who have previously been treated with the drug lenalidomide
• People who received CAR-T cell therapy within 100 days before starting trial treatment
• People who have a stem cell transplant or maintenance therapy planned within 24 weeks of starting the trial (those planning these after at least 24 weeks of treatment may still be considered eligible)
• People whose doctor plans to use a platinum-based chemotherapy combination as part of their treatment
• People who have HIV or uncontrolled hepatitis C virus (HCV)
• People who test positive for active hepatitis B virus (detectable viral DNA or a positive hepatitis B surface antigen test); those who show a past exposure marker but have no detectable virus in the blood may still be considered eligible
• People who have had another cancer within the past 2 years, with some exceptions such as early-stage cervical cancer, certain non-invasive skin cancers, superficial bladder cancer, well-controlled prostate cancer, or any cancer that has been fully cured for more than 2 years (confirm with trial site)
• People who currently have an active infection requiring treatment
• People whose lymphoma has spread to the brain or spinal cord, either currently or in the past
• People who have had a serious allergic reaction to anti-CD20 antibody treatments (such as rituximab or obinutuzumab)
• People who have a known allergy or sensitivity to the specific trial drugs being studied (those with a sensitivity to one treatment option may still be considered eligible if other options are available)
• People with serious medical or mental health conditions that would make it difficult to take part in the trial
• People who have received chemotherapy, immunotherapy, or other cancer treatments within 4 weeks of starting the trial, or who have been on higher-dose steroid treatment within 7 days of the first dose
• People who are unwilling to use appropriate contraception during treatment and for 12 months after finishing (or 18 months for women receiving a regimen containing obinutuzumab)
• Women who are pregnant or breastfeeding
• People who have previously received the specific experimental treatment being tested in this trial
• People who have had major surgery within 30 days of starting treatment
• People with certain serious heart conditions, depending on which treatment regimen is being considered (confirm with trial site for details relevant to specific treatment options)

Important: Always verify eligibility with the trial site directly before applying.